

COVID-19 Omicron Variant (B.1.1.529) Coronavirus Pseudovirus | COVID-19 pseudovirus

SARS-CoV-2 Pseudoviral Particles, Omicron Variant (B.1.1.529)

CATALOG #
AAA62235


PRODUCT SYNONYMS

COVID-19 Omicron Variant (B.1.1.529) Coronavirus; SARS-CoV-2 Pseudoviral Particles; Omicron Variant (B.1.1.529); 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; COVID-19 pseudovirus

PRODUCT SPECIFICATIONS


Features	Robust: Excellent signal to noise (basal) ratio Easy to use: Amenable to HTS format (96-well, 384-well and 1536-well format)
Contents	10 ml (2 tubes, 5 mL/tube), for 2 multi-well plates; PP per mL > 1.0E+07
Dry Ice Note	The product may be shipped with dry ice, and an additional fee may be added to your shipping cost.
Preparation and Storage	Upon receipt, store at -70°C right away. Thaw* before immediate use. *Note: read the instruction for thawing in the following protocol carefully. Do not aliquot and refreeze. Shelf Life: Six months from the date of receipt when stored at -70°C Dry Ice Shipment: Extra charge fee may add to your shipping cost as dry ice is required to ship this product. Shipping Note: Product is available for shipment in the United States, Canada and European countries. Please inquire for shipment to other countries.

IMAGES




Application Data

Figure 4. Antibody (Ab) Neutralization Assays with SARS-CoV-2-614G-PP




Application Data

Figure 3. Antibody neutralization assays using Omicron pseudoviral particle (PP) infection method. Each antibody dose-response curve represents the relative infectivity under serial dilutions of antibody. At each Ab concentration, HEK293-ACE2 cells were co-incubated with SARS-CoV-2 Omicron pseudoviral particles in the presence of the antibody. Among the 3 antibodies tested, Ab1 and Ab2 showed good neutralization capacity towards Omicron spike.



Application Data

Figure 2. Pseudoviral Particle (PP) Infection assays (SARS-CoV-2-Omicron variant pseudoviral particles on HEK293-ACE2 cells)Legends: SARS-CoV-2 Omicron variant MLV pseudovirus particles (AAA62235) (-): MLV control (w/o envelope spike protein



Application Data

Figure 1. Illustration of the replication-deficient MLV particle pseudotyped with SARS-CoV-2 Spike protein

ADDITIONAL INFORMATION

Related Product Information for COVID-19 pseudovirus

It has been known that SARS coronavirus 2 (SARS-CoV-2) uses human ACE2 as entry receptor and human proteases as entry activators. The virus surface spike protein (S) mediates SARS-CoV-2 entry into cells. To fulfill its function, SARS-CoV-2 spike binds to its human ACE2 (hACE2) receptor through its receptor-binding domain (RBD) and is proteolytically activated by human proteases.

Our SARS-CoV-2-Omicron Pseudoviral Particles are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein (Accession ID: EPI_ISL_6699757) of the Omicron variant, originally known as lineage B.1.1.529. They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus cell entry assay mediated by the SARS-CoV-2 spike protein that can be conveniently measured via luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com

Online datasheet: <https://stage.aaabiotech.com/pseudovirus/covid-19-omicron-variant-b-1-1-529-coronavirus/62235>